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Abstract 
 
McNichol, Ryan Matthew. M.S., Department of Microbiology and Immunology, Wright 
State University, 2007. 
Characteristics of a Foamy Virus-Derived Vector that allow for safe autologous gene 
therapy to correct Leukocyte Adhesion Deficiency Type 1. 
 
The hematopoeitic stem cell is a prime target for gene therapy in the attempt to correct a 
number of single gene inherited genetic defects that affect the immune system.  In persons 
affected by leukocyte adhesion deficiency type 1 (LAD-1) the gene for the Beta-2 subunit of the 
integrin molecule is mutated.  This autosomal recessive gene defect yields a phenotype with little 
or no beta-2 integrin expression on leukocytes.  Beta-2 integrin expression is essential for 
leukocytes to travel from the blood to the tissues to fight infection.  Persons with this disease 
have lowered leukocyte counts in the tissues and as a result are beset with recurrent infections 
which often cause death within the first year of life.  As an alternative to using sibling bone 
marrow transplants, a treatment using retroviral vectors in autologous gene therapy is being 
studied to correct the disease.  Problems surrounding retroviral vectors include 1) a dependence 
on cell division for integration, 2) short term transgene expression, 3) insertional mutagenesis 
and 4) the potential of becoming replication competent.  The latest alternative in the treatment of 
LAD-1 is the use of vectors derived from human foamy viruses.  These viruses show no human 
pathogenicity.  The foamy viruses have displayed promising integration patterns in cells and are 
able to survive in quiescent cells that will later divide.   Furthermore, these viruses can be 
modified to become replication incompetent.  Using the promoter sequence for the integrin 
subunit CD18 to direct transgene expression will further increase the safety of this vector in 
treating LAD-1.   
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INTRODUCTION 
 
 Hematopoeitic stem cells (HSCs) are the self renewing adult stem cell population 
in the bone marrow which gives rise to all the cell types in the blood.  The HSCs undergo 
asymmetric cell division and eventually give rise to lymphoid and myeloid progenitors.  
The lymphoid progenitors divide and further differentiate to become the thymocytes in 
the thymus, the B-cell precursors in the bone marrow, and the natural killer cells.  The 
myeloid progenitors also divide and further differentiate to become mast cells, 
neutrophils, eosinophils, basophils, erythrocytes, the platelet producing megakaryocytes 
and the blood monocytes which give rise to tissue macrophages.  Dendritic cells arise 
from both the lymphoid and myeloid progenitors (29, 47). 
 
Figure 1. Origin of the Cells of the Immune System   
Adapted from http://stemcells.nih.gov/info/scireport/chapter5.asp 
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The immune cells, red blood cells and megakaryocytes derived from HSCs will 
sometimes have malfunctioning proteins or even lack certain cell surface and intracellular 
signaling proteins.  The result is a variety of blood diseases.  These problems make the 
HSC population an attractive target for viral vector-mediated gene therapy to correct a 
number of genetically inherited diseases.  Some of these target diseases include sickle 
cell anemia (49), beta-thalassemia (44), adenosine deaminase-deficient severe combined 
immunodeficiency (ADA SCID) (27), X-linked SCID (16), X-linked 
agammaglobulinemia (67), chronic granulomatous disease (22), Wiskott-Aldrich 
syndrome (55), and leukocyte adhesion deficiency type 1 (LAD-1) (13), a very rare 
disorder in which neutrophil migration is impaired. 
 
NEUTROPHILS  
 The cells that are primarily responsible for clearing infectious agents from the 
body are the phagocytes, the macrophages and the neutrophils.  The most abundant of 
these cell types is the neutrophil, which comprises over 50% of the total circulating white 
blood cells.  Due to their short 12-16 day life span neutrophils are produced at a rate of 
100 billion cells per day (14, 25, 66).  Three billion of these cells daily travel to the 
mucosal tissues of the nose and throat to protect these areas of high pathogen exposure.  
This cell type is also known as the polymorphonuclear neutrophil leukocyte and is easily 
distinguished from eosinophils and basophils by its multilobed nucleus (figure 2) (29).  
Neutrophils originate in the bone marrow and circulate in the blood until they are 
summoned to enter infected tissue by complement proteins or inflammatory signals from 
the site of an infection.  Neutrophils move from the blood stream to the tissue by 
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squeezing between endothelial cells of the blood vessel wall, a process called diapedesis, 
and follow a chemokine gradient to the site of infection to phagocytose pathogenic 
invaders.  The engulfed pathogens are safely destroyed by reactive oxygen species and 
microbicidal proteins while causing little or no damage to surrounding tissue (29, 47, 66).  
After having carried out their function, neutrophils then begin to undergo apoptosis and 
are ingested by macrophages.  The average lifespan of a mature neutrophil is 12-16 days 
(14, 25, 66). 
 
Figure 2.  Diagram and Light Microscope Image of a Neutrophil 
 
Adapted from Parham, The Immune System 2nd ed. 2005 
 
Neutrophil Development 
 The development of a Neutrophil in the bone marrow from its most immature 
precursor to a fully functional mature phagocyte includes six stages.  The stages are: 
Myeloblast → Promyelocyte → Myelocyte → Metamyelocyte → Band →Mature 
Polymorphonuclear Neutrophil (Figure 3) (5).  The first three stages of development are 
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mitotic while the last three are not mitotic.  During the promyelocyte, myelocyte, 
metamyelocyte and band stages of development the azurophilic, specific and gelatinase 
granules are produced.  The azurophilic and specific granules are produced in the 
promyelocyte and myelocyte stages respectively and contain mainly the potent 
microbicidal proteins that the neutrophil uses to destroy pathogens.  The granules act on 
the invading pathogen in one of two ways.  The granules are delivered to the phagosome 
or they are exocytosed to destroy foreign invaders in the extracellular matrix.  The 
gelatinase granules are composed primarily of metalloproteases capable of cleaving the 
constituents of the basement membrane and extracellular matrix and allow the neutrophil 
to move out of the blood stream and migrate through the tissues (20).   
After development, neutrophils can be found in the bone marrow, the blood 
stream, or in the tissues.  In the blood, neutrophils are classified as one of two types based 
on their relationship to the vascular endothelial wall.  The neutrophils which move slowly 
through circulation making brief, reversible, attachments to the blood vessel wall are 
called marginal neutrophils while freely circulating neutrophils are referred to as 
circulating neutrophils (5, 14, 25).    
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Figure 3.  Development of a Neutrophil 
 
Adapted from Bainton et al. 1971 
 
 
Neutrophil Migration 
Mature neutrophils in the bone marrow are summoned into the blood by the 
inflammatory cytokines interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis 
factor-α (TNF-α).  Neutrophils in the blood can be converted from circulating neutrophils 
to marginal neutrophils through the function of selectins.  Chemokines and cytokines 
released by tissue macrophages induce the expression of L-selectin on neutrophils and E- 
and P-selectins on vascular endothelial cells at the post-capillary venule.  Selectins make 
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transient attachments to their carbohydrate ligands on an opposing surface to mediate 
“neutrophil rolling” where neutrophils roll along the blood vessel wall prior to migration 
into tissues.  E- and P-selectins bind to the carbodrate molecules sialyl-Lewis X and P-
selectin Glycoprotein Ligand-1 (PSGL-1) of neutrophils respectively.  L-selectins bind to 
sulfated sialyl-Lewis X of the endothelial cell surface.  Rolling is a prerequisite for 
neutrophils that migrate from the blood to the site of infected or inflamed tissue (14, 25, 
29, 47, 66).   
 The next step in migration involves the interaction of integrin molecules on the 
neutrophil with intercellular adhesion molecules (ICAMs) on the endothelial cell.  This 
interaction mediates the events of arrest and migration across the blood vessel wall at the 
site of infection or inflammation.  The integrins CD11a/CD18 (leukocyte functional 
antigen-1 (LFA-1)), CD11b/CD18 (Mac-1 or complement receptor 3 (CR3)) and 
CD11c/CD18 (p150,95) are composed of an alpha protein (CD11) and a beta-2 protein 
(CD18).  These are the three main integrins involved in arresting the neutrophil.  The 
beta-2 protein of this pair of integrin molecules assumes an active form when neutrophils 
are exposed to inflammatory chemoattractants such as C5a, and IL-8.  These 
chemoattractants not only increase the integrin affinity for ICAMs but they also induce 
the neutrophil to discard L-selectin molecules.  On the endothelial cell, the ICAM-1 is 
upregulated mainly by the inflammatory cytokines interleukin-1 (IL-1) and tumor 
necrosis factor-α (TNF-α).  The activated integrin molecule attached to the ICAM then 
brings the rolling neutrophil to rest and sets the stage for transmigration across the 
endothelial wall (14, 25, 29, 47, 66). 
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 At the stage of arrest, the neutrophil crosses the endothelial wall through the 
interaction of platelet endothelial cell adhesion molecule-1 (PECAM-1) (also known as 
CD31).  PECAM-1 is expressed both on neutrophils and at the junction between 
endothelial cells.  At this intercellular junction, CD31 on neutrophils binds to CD31 on 
the endothelial cell to perform transmigration (25, 29, 47, 66). 
 
Figure 4.  Extravasation of a Neutrophil From the Blood to the Tissues 
Adapted from Parham, 2001  
 
 
 At this point the only remaining barrier between the neutrophil and the intended 
tissue is the basement membrane of the post capillary venule wall.  The activated 
neutrophil releases enzymes from its gelatinase granules known as collagenolytic 
metalloproteases which are responsible for cleaving the basement membrane of the blood 
vessel wall (20). 
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Following the neutrophil entry into the tissues it migrates to the foreign invader 
that elicited its migration.  The neutrophil travels to the pathogen along a chemical 
gradient by an amoeboid movement.  Some of the chemoattractants for which the 
neutrophil possesses receptors are C5a (a product of the complement cascade), C5a des 
Arg (a processed form of C5a), interleukin-8 (IL-8) (also known as the chemokine 
CXCL8) and proteins containing N-formylmethionine (an amino acid found only on 
bacterial proteins) (66).    
 
Phagocytosis 
 A neutrophil expresses a variety of cell surface molecules by which it recognizes 
foreign invaders and discriminates against human tissue.  Infectious bacteria possess 
pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) on 
their surface.  The neutrophil will bind to LPS by its CD14 and CR4 receptors to initiate 
phagocytosis.  The neutrophil can also bind to opsonins such as complement protein and 
antibody which coat the surface of the pathogen.  Complement receptor 3 (also known as 
CD11b/CD18) binds to the abundant complement protein C3b while the Fc receptor 
binds to the Fc region of pathogen bound antibody (14, 25, 29, 47, 66). 
The process of engulfment (endocytosis) follows pathogen binding and 
psuedopods of the neutrophil project out around the bound pathogen and fuse together to 
form a phagosome, a membrane bound chamber within the neutrophil.  It is in the 
phagosome that killing and degradation take place.  Many mechanisms are responsible 
for dismantling the engulfed pathogen, but they can be simplified into two main 
categories: those processes that involve microbicidal proteins released during the 
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formation of the phagolysosome and those that involve the generation of reactive oxygen 
species (ROS).  Generation of ROS is initiated when the neutrophil’s integrin molecule 
binds to an ICAM (66).          
  
Apoptosis and Clearance 
 The neutrophil’s lifespan ends with programmed cell death.  During this process 
the phospholipid, phosphatidyl-serine (PS) is exposed to the outer leaflet of the 
neutrophil membrane.  The PS receptors of the macrophage bind to the exposed PS and 
engulf the dead neutrophil (14). 
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LEUKOCYTE ADHESION DEFICIENCY TYPE 1 
 Leukocyte adhesion deficiency type 1 (LAD-1) is a defect in which the expression 
of the three main leukocyte integrin molecules LFA-1, Mac-1 and p150,95 is decreased, 
completely absent, or expressed but nonfunctional.  These molecules are responsible for 
allowing leukocytes to firmly attach to blood vessel walls and transmigrate into the 
tissues.  The integrin molecules allow leukocytes to bind to each other and also to 
intercellular adhesion molecule-1 (ICAM-1) on activated endothelial cells of the post 
capillary wall.   These three integrin molecules consist of different alpha-1 subunits 
(CD11a in LFA-1, CD11b in Mac-1, CD11c in p150,95) and a common beta-2 subunit 
(CD18) which pairs with the alpha subunit in the assembly of each of these molecules.  
The alpha and beta subunits are separately translated, undergo carbohydrate additions, 
and paired with each other for transport to the cell surface (53).    
 
Figure 5.  Diagram of a Beta-2 Integrin Molecule with Alpha and Beta Subunits                                  
                     
   Adapted from www.medicine.ox.ac.uk/ndog/mardon/integrin.htm  
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The gene for the beta-2 subunit contains 16 exons and stretches about 40 
kilobases.  Along this region of DNA a variety of mutations may occur.  Three main 
types of mutations give rise to the disease phenotype.  The first type of mutation alters 
the region of the beta-2 subunit known as the I-domain which is encoded by exons 5-9 of 
the gene.  Such a mutation may decrease the ability of the beta-2 subunit to pair with one 
of its three alpha partners, but more importantly will decrease the ability of the beta-2 
integrin to bind to its ICAM ligands (6).  The second type of mutation affects the 13th 
exon of the beta-2 subunit gene.  This region of the gene encodes for a cysteine rich 
region that gives stability to the protein through multiple disulfide bonds within the beta-
2 subunit (51).  The third type of mutation affects the ability of the beta-2 mRNA to 
splice.  This mutation, which can occur at any exon/intron border within the gene, alters 
splice acceptor or donor sites and gives a resulting larger-than-usual mRNA molecule 
which in turn is not translated into the beta-2 subunit (51).    
 
Figure 6.  Gene organization of the CD18 subunit (exons represented by black bars) 
 
Adapted from Weitzman et al., 1991 
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As stated above, in LAD-1 patients, a mutation in the gene for the common beta-2 
subunit results in little or absent expression on the leukocyte cell membrane (53).  The 
cell types that are most affected by this mutation are the macrophages and neutrophils.  
As neutrophils are clearly the most abundant white blood cell type, their levels in blood 
and tissue are used to measure disease severity.  B and T lymphocytes have other 
adhesion molecules which can compensate for the loss CD11/CD18 heterodimers and are 
thus able to perform adhesion in LAD-1 patients (3).   
The percentage of CD18 protein expression corresponds with the level of disease 
severity.  Those patients that express less than 1% of normal levels of functional integrins 
are said to have the severe form of the disease, whereas patients whose levels are in the 
1% to 10% range have the mild form of the disease.  Those born with severe LAD-1 
often die by the age of 1 and those with milder forms of the disease rarely live beyond 
their 40s (41, 42).  Persons who are heterozygous for a LAD-1 mutation have about 50% 
of blood neutrophils expressing functional integrins and exhibit no disease phenotype 
(41). 
Patients with LAD-1 usually have chronic bacterial infections with 
Staphylococcus aureus and Escherichia coli, and fungal infections like Candida and 
Aspergillus (42).  Infections of this nature necessitate regular antibiotic/antifungal 
treatment and frequent transfusions with normal granulocytes.  Another treatment option 
is bone marrow transplantation, but as with granulocyte transfusion, there always exists 
the risk of graft rejection through alloantibody formation (3).   
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GENE THERAPY HISTORY OF LAD-1 
 Before gene therapy could be considered to treat LAD-1, researchers needed to 
uncover the molecular basis of the disease and the gene or genes affected.  The molecular 
basis was discovered when a hybrid experiment was performed with T cells from a 
patient with LAD-1 and normal mouse T cells.  Before fusion of the cells, the T cells 
from the LAD-1 patient expressed neither the alpha nor the beta subunit of the integrin 
LFA-1 on their surface.  After fusion, it was apparent that the human alpha protein 
coupled with the mouse beta protein to form a hybrid LFA-1 integrin molecule that could 
be expressed at the cell surface of the hybrid cell.  None of the resulting hybrids in this 
study expressed the human derived beta-2 subunit.  This finding allowed researchers to 
trace the genetic defect of LAD-1 to the gene encoding the beta-2 subunit of the integrin 
molecule (43).  The gene for this common beta-2 subunit was later discovered to be on 
chromosome 21 (64).  The gene spans about 40 kilobases and contains 16 exons, but its 
coding sequence alone was determined to be a mere 2.3 kilobases (64).  The largest 
transgene sequence that can be accommodated by a retroviral vector is 9.2 kilobases (58); 
therefore, LAD-1 is an ideal candidate for retroviral-mediated gene therapy (4).    
 Based on the above findings, some laboratories began to use various viral vectors 
to transfect and transduce the CD18 gene into cells from LAD-1 patients.  These early 
studies relied on EBV-, RSV-, and Moloney MLV-based vector systems and EBV 
transformed cell lines derived from LAD-1 subjects (4, 11, 26, 65).  The next step toward 
correction of this disease began with a clinical trial where the Moloney MLV-based 
vector system was used to target the CD34+ cells from two patients with the severe form 
of LAD-1.  The CD34+ cells were obtained and purified from the peripheral blood 
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through G-CSF-induced mobilization followed by apheresis and CD34+ HSC 
purification.  Researchers attempted to transduce the hematopoeitic stem cells of these 
LAD-1 patients ex vivo and then reintroduce these cells into these patients, with the hope 
that their own gene-corrected stem cells would give rise to gene corrected progeny in 
vivo.  These patients both exhibited a temporary increase of more than double the 
percentage CD18+ neutrophils in the blood and a temporary improvement of disease 
phenotype.  These researchers concluded that the procedure with this vector system 
required further enhancement and modification (personal communication with Dennis 
Hickstein and Thomas Bauer, unpublished results from 1999).  Later, this lab concluded 
that the temporary cure seen in this patient was due to the fact that the oncoretroviral 
vector requires cell division to integrate its target cell (10).  Therefore, there are two 
possible explanations for this failed gene therapy trial.  1) The cell that these vectors 
transduced was not the HSC but the transient myeloid progenitor.  2) It is possible that 
this vector did transduce the HSC but that the forced ex vivo cell division by multiple 
growth factors caused both of this cell’s daughters to become committed myeloid 
progenitors (23).    
 
FURTHER STEPS IN GENE THERAPY TREATMENT OF LAD-1 
 At present, dogs with Canine Leukocyte Adhesion Deficiency type 1 (CLAD-1) 
are being used to test autologous HSC therapy in hope that the therapy could be 
successfully used in humans.  In the treatment of CLAD-1, bone marrow transplantation 
has been used to successfully correct CLAD-1.  While bone transplantation has a history 
of failure with human LAD-1 patients (57), this large animal bone marrow 
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transplantation revealed that only a small increase in the number of CD18 expressing 
neutrophils is sufficient to reverse or improve the disease phenotype (8).  Persons who 
are heterozygous for a LAD-1 mutation will exhibit no disease phenotype and these 
persons express at most 50% of the normal amounts of CD18 on their neutrophils (41), 
while those with the most moderate phenotype of the disease can express up to 31% of 
normal levels on their neutrophils (2).  In view of these points, it is clear that this disease 
only requires partial restoration of normal numbers of CD18 expression on neutrophils in 
order for the disease phenotype to be reversed.    
The goal of autologous gene therapy experiments is that the virally transduced 
autologous cell (the HSC) will persist in the patients and permanently give rise to gene 
corrected immune cell types to improve or reverse the disease phenotype.  The only viral 
vectors which are capable of this kind of cure are the retroviruses because only this 
family of viruses is capable of integration into the target cell chromatin (32).  This goal 
has been reached in Irish Setters with CLAD on two separate occasions where two 
different retroviral vectors were employed.  In the first of these two studies the foamy 
virus-derived vector was used to completely reverse the disease phenotype in four out of 
five dogs.  All four of these dogs are completely disease free and have not required 
antibiotics at two years post- treatment (Personal Communication with Dennis Hickstein, 
unpublished data from 2005).  In another experiment, six out of 11 treated dogs had the 
disease phenotype reversed or improved using an MLV-derived vector and reinfusing ex 
vivo corrected HSCs.  Slight increases in CD18+ neutrophil levels were maintained up to 
21 months following treatment (9).  HIV-1-derived vectors have also been used in 
attempt to correct other blood diseases (44, 49) in small animal models, but never in 
 16
LAD-1 studies.  The lentiviruses will be discussed as they have a significant advantage 
over the oncoretroviruses for delivering gene to the HSC. 
 
The Problems with Retroviral Vectors    
 The preintegration complex of an MLV-derived vector is too large to pass through 
the nuclear envelope of a non-dividing cell (i.e. HSCs) (59).  Therefore, in order for 
integration to take place using these popular vectors, HSCs must be forced to divide.  
Forcing a stem cell to divide can be detrimental to the goal of achieving a permanent cure 
because if the cell is exposed to growth factors for a long enough period of time the cell 
may differentiate (21).  Although integration will be accomplished, the daughter cells of 
the HSC might be committed to myeloid or lymphoid progenitors which have a limited 
lifespan in vivo.  This commitment to a progenitor was the explanation for the failure of 
an early LAD-1 clinical trial (10). 
Retroviral vectors still remain as attractive tools for gene therapy because they are 
capable of integrating genetic information into target cells.  If the vector is derived from a 
lentivirus, it can integrate into non-dividing cells.   However, the retroviruses exhibit 
preferential integration (figure 7).  Preference for integration into active genes has been 
seen in Beta-globin gene transduction with HIV-1-derived vectors (28, 62).  Preference 
for integration close to promoter sequences has also been observed in γ chain gene 
transduction with MLV-derived vectors (24, 62)  The dangers of the MLV integration 
preference have been demonstrated in an X-linked SCID trial where 2 of 11 young 
patients after having received successful HSC correction (16) later developed leukemia.  
The retroviral integration in both of these leukemia patients was found near the promoter 
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for the LMO-2 gene, a proto-oncogene that is normally only expressed in progenitor cells 
(24). 
 
 
Figure 7.  Areas of Common Integration by Oncoretroviruses and Lentiviruses  
Adapted from von Kalle et al. 2004 
 
Additionally, replication competent retrovirus (RCR) may form via recombination 
during vector production.  While HIV-1-derived vectors have been generated that are 
claimed to be self-inactivating, these viruses can still rebuild their promoter region even 
after significant deletion (19, 68).  The process involved in producing such vectors 
involves much risk as a single genetic recombination event can mean the generation of 
one replication competent retrovirus.  Furthermore, HIV-1 and MLV do not naturally 
infect HSCs and for this reason these viruses need to be psuedotyped with an envelope 
protein that allows entry into this cell type.  If a recombination event occurred that 
produced a broad host tropic HIV-1 virus, the result could be the production of a more 
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harmful virus than the pre-existing wild-type HIV-1 (18).  However, such an event is 
very unlikely as the genes that are used to produce these vectors are located on three or 
four separate plasmids within producer cells.  Nevertheless, the risks involved in 
manipulating this deadly pathogen have not been completely eliminated (18).     
 Taken together, retroviral vectors show three major problems.  1) The 
oncoretroviruses cannot infect non-dividing cells.  These viruses may not survive in a 
quiescent cell during the G0 and G1 phases of the cell cycle since they lack sufficient 
nucleotide pools required for reverse transcription prior to nuclear entry (59).  These 
nucleotide pools are also required for HIV-1 as seen by the fact that they transduce 
dividing cells more efficiently than quiescent cells (59).  2) The oncoretroviruses and 
lentiviruses have dangerous integration preferences putting stem cells at risk for 
insertional mutagenesis (62).  3) Genetic recombination puts labs at risk for producing 
highly pathogenic replication competent retroviruses (RCR) (18).  
 
Table 1.  Problems With Current Retroviral Vectors 
 
 
 
 Cell Cycle 
Requirement 
Integration 
Preference 
RCR? 
Oncoretroviruses Mitosis Upstream of 
promoters 
Risk not 
completely 
eliminated 
Lentiviruses None Within active 
genes 
Risk not 
completely 
eliminated 
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FOAMY VIRUSES 
 The foamy viruses, named for the characteristic foamy appearance that they 
produce in culture, have not been heavily researched until recently.  These viruses, of the 
spumavirus subfamily, are endogenous in animals and they have also been isolated from 
humans.  In 1971 the first human foamy virus (HFV) was isolated from the nasopharynx 
of a Kenyan man.  The closest characterized relative of the “HFV” is the SFVcpz isolated 
from a chimpanzee species which is native to Kenya (1).  It is still debated as to whether 
or not there is an actual human variant of this virus.  Most researchers claim that the virus 
isolated from a human specimen in 1971 is possibly a primate variant that the specimen 
received by animal to human transmission.  Therefore, while the use of the letters HFV is 
common, it should probably be called SFVcpz(hu) (38).    
 
Figure 8.  Electron Micrograph of Budding Foamy Viruses 
 
Adapted from Hooks and Gibbs. 1975 
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While having the typical gag, pol and env genes that are characteristic of all 
retroviruses, these viruses are unique in that they seem to be dsDNA viruses.  The reason 
for this classification lies in a distinct feature of their life cycle where reverse 
transcription happens just prior to budding (50, 52).  Another unique feature of the foamy 
virus life cycle is their gene regulation.  The foamy viruses have two promoters, the LTR 
and an internal promoter (IP) near the end of the env gene.  Both promoters are driven by 
the non-structural tas (transactivator of spumavirus) protein (50).  This protein is also 
known as the bel-1 gene product (figure 8).   
 
Figure 9.  The Human Foamy Virus Genome 
 
Adapted from Vassilopoulos et al. 2001 
 
 
While the IP has a basal level of activity the LTR is transcriptionally inactive 
without tas binding (40).  The fact that the LTRs are transcriptionally inactive without tas 
is an excellent safety feature in light of this virus being a gene delivery tool.  Foamy 
vectors constructed without the tas protein are unable to induce expression of nearby 
genes (7).  Foamy viruses further deviate from the other retroviruses in that many virions 
never become extracellular viruses but remain associated with the plasma membrane; 
their foamy appearance in culture results from syncytial formation (39).  Another unique 
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feature of the foamy virus when compared to other retroviruses is their co-requirement of 
gag and env for budding and infectivity (37).  The env protein is processed into three 
subunits after translation: a leader peptide (LP) at the N-terminus, a surface subunit (SU) 
and a transmembrane subunit (TM).  The env protein is processed by cellular furin-like 
cellular proteases and must be cleaved at least into SU and TM subunits to be capable of 
producing infection.  The LP of env and the N-terminus of gag interact with each other.  
This interaction is required in order for HFV capsids to be incorporated into the HFV 
envelope (37). 
 
Figure 10.  The Life Cycle of the Human Foamy Virus 
 
Adapted from Linial 1999  
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Foamy Virus Vectors: Advantages 
Foamy viruses have been reported to persist in humans for up to 20 years without 
any pathogenic activity.  A number of comprehensive studies, each of which used several 
assays to confirm the presence of the virus (Table 2), have failed to attribute any disease 
condition to the virus (45).  Such a quality makes this virus an excellent choice as a gene 
therapy vector. 
 
Table 2.  Disease Association with Foamy Viruses 
 
Adapted from Meiering and Linial 200l 
 
 Foamy virus vectors have cell cycle requirements that are lower than the MLV-
derived vectors, which require cell division, yet higher than the HIV-1-derived vectors, 
which do not require cell division.  Another suitable quality of foamy viruses is their 
ability to persist at the microtubule organizing center (MTOC) of non-dividing cell types 
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that will divide later (36, 59, 61).  This ability to survive in the G0 and G1 cell cycle 
environment is due to fact that these viruses have already reverse transcribed and do not 
require any cellular nucleotide pools before entry into the nucleus (59).  In order to 
integrate genetic information, they only require cell cycle progression into the G1/S phase 
(48, 59).  The events taking place that allow the preintegration complex to migrate 
through the Ran GTPase-controlled nuclear pore complex at G1/S phase are still a 
mystery (56).  However, it is known that prior to nuclear entry, FV gag processing and 
viral capsid disassembly occur and this gag activity is totally dependent on some 
unknown cellular factor which is probably linked with cell cycle progression into G1/S at 
the MTOC (figure 11) (35). 
 
Figure 11.  Foamy Virus Capsid Disassembly and Nuclear Import 
   
Adapted from Lehmann-Che et al. 2005  
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An additional feature of the foamy virus vector that sets it apart from the 
lentiviruses and oncoretroviruses is its integration patterns in infected cell types.  In 
contrast to the lentiviruses and oncoretroviruses, the foamy viruses do not show a 
preference for integrating within active genes nor do they show a preference for 
transcriptional start sites (46).  Furthermore, the HFV vector integration with respect to 
the LMO-2 proto-oncogene was about 700 kb from the gene’s start site.  Although these 
data appear promising, this study does not report on the effects that a constitutive 
promoter would have on nearby genes (60).   
The foamy viruses seem to have unique characteristics that serve as solutions to 
the above three fundamental problems found in the other retroviral vectors.  These 
vectors 1) are non-pathogenic in humans (45), 2) they are able to persist in non-dividing 
cell types in culture which will later be stimulated to divide (48, 59), 3) they appear to 
have significantly reduced risk of insertional mutagenesis compared with the other 
retroviral vectors (46, 60) and it is possible to generate a safe, self-inactivating vector 
using these viruses (7).  Based on a recent success in the treatment of CLAD in Irish 
setters, the NIH is considering a clinical trial with humans who have LAD-1 and are 
using a newer and presumably safer HFV-derived vector (personal communication w/ 
Hickstein and Bauer, unpublished data).  These vectors are potentially the next great tool 
to correct LAD-1 as well as a number of other genetic immunodeficiencies. 
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Disadvantages of the Foamy Virus Vectors 
While the foamy viruses appear to be a more suitable vector than the other 
retroviruses the amount of virus that can be generated by packaging cells is quite low.  A 
small percentage of the virons generated within a producing cell will actually bud and 
become extracellular particles.  The reason for the low production of extracellular virus is 
that the leader peptide of the envelope protein in foamy viruses is often ubiquitinated 
during assembly and ushered to the proteasome for destruction.  This leader peptide is 
absolutely required for the foamy virus to bud from the cell (54).  The LP is so often 
ubiquitinated and destroyed, that the foamy virus is left with an incomplete env protein 
that is incapable of allowing the virus to bud (54).  The result is that there are many cell 
membrane-associated virions and few viruses which are able to transfer gene to a target 
cell.  The target cell of the foamy virus vector in an autologous gene therapy experiment 
to correct LAD-1 is the patient’s HSC.  This cell type has a low amount of foamy virus 
receptor (63).  The low amount of Foamy receptor coupled with the low number of 
extracellular viruses produced by a packaging cell line leaves the foamy virus with a 
lower possibility of delivering the gene for the CD18 subunit into the HSC.  However, 
such disadvantages pale in comparison to this virus’s biosafety features and stability 
within the quiescent cell.      
 
Promoters used to Drive expression of the Beta Subunit Gene 
The promoters that are most often used in retroviral vectors to direct the 
expression of the gene of interest are the Cytomeglovirus (CMV) promoter, the MLV 
 26
promoter and the phosphoglycerine kinase (PGK) promoter.  A potential problem with 
any retroviral vector is that using of one of these constitutive promoters has the potential 
cause inappropriate expression of nearby genes.  The key to solving this problem will be 
the integrin promoter for the CD18 subunit gene.  This promoter is myeloid tissue 
specific and has been used in previous MLV-derived vector systems albeit with little 
success (12).      
 
HEMATOPOIETIC STEM CELLS: The Target Cell of the Autologous 
Gene Therapy Experiment to Correct LAD-1 
 
 The CD34+ Hematopoietic stem cell is the target cell that needs to be harvested, 
transfected by the retrovirus-derived vector, and reintroduced back into LAD-1 patients 
(9).  Therefore, it is important to understand how researchers are attempting to preserve 
the “stemness” of this cell population during an ex vivo autologous gene therapy 
experiment.  As stated earlier, this cell population may differentiate in the presence of 
growth factors ex vivo.  One method that is being practiced to attempt to ensure that the 
trandsduced HSCs retain their “stemness” is a shorter transduction protocol.  The 
duration of these protocols when using retrovirus-derived vectors have been reported to 
be as short as 24 hours (9) with MLV vectors, 18 (33) and 10 hours (30, 31) when using 
FV vectors, and even 1hour when using HIV vectors (34).  The results of all these studies 
were that gene corrected progeny could be observed long after the stem cell transduction 
and reinfusion.  However, just the fact that these cells are exposed to growth factors 
could diminish their repopulating capacity even if these cells remain in the G0 phase of 
the cell cycle (23).  Since the FV vectors do not need circulating nucleotide pools (59) 
and are able to survive as a stable transduction intermediate at the microtubule organizing 
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center (MTOC) for at least 30 days in quiescent cells (36) it is not necessary to even 
expose HSCs to growth factors when using this vector.  While the HSCs normally divide 
on average once every 30 days in the normal bone marrow microenvironment (15, 17), 
reinfusion of gene corrected HSCs could prompt them to cycle earlier, allowing the FV 
vector to enter the nucleus (36).  Therefore, the use of a FV vector eliminates the need to 
place the HSCs in conditions that will jeopardize their long-term repopulating capacity.                    
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Possible Vector Design and Experimental Diagram 
Figure 12. Foamy Virus Vector Production and Transduction
LTR     Gag      Env Remnant overlap     CD18 promoter 
Pol         and gene   LTR
Nucleus
Packaging Cell
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Env gene
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Nucleus
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intermediate during the G0 phase 
of the cell cycle until reinfusion of 
HSC back into the LAD-1 patient
Vector Fusion and 
Transduction
Ex vivo
 
 29
CONCLUSIONS 
 In the near future LAD-1 patients should benefit from the use of Foamy Virus-
derived vectors in autologous gene therapy.  This retrovirus is non-pathogenic and able to 
integrate genetic information into the chromosome for long term gene expression.  Also, 
this virus has a unique cell cycle requirement that will allow hematopoietic stem cells to 
maintain their “stemness”.  Forced division of the stem cell in vitro may cause it to 
become a progenitor with a limited life span, leading to a mere temporary disease 
correction.  Furthermore, some single gene blood diseases require a complete correction 
to reverse the phenotype of the disease.  LAD-1 is an autosomal recessive genetic defect 
and will require at most 50% of normal levels of CD18 expression on neutrophils in order 
for the disease phenotype to be reversed.  In addressing the matter of insertional 
mutagenesis, the FV LTRs are inactive in the absence of the tas protein.  These vectors 
will be unable to cause an inappropriate overexpression of nearby genes.  In addition, 
foamy virus vectors that have a tissue specific CD18 integrin promoter will be 
exceptionally safer than those possessing constitutive promoters used in previous studies.       
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